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Abstract
Background Non-vitamin K antagonist oral anticoag-
ulants (NOACs) are prescribed to patients with atrial
fibrillation (AF) to reduce the risk of stroke. Prescrib-
ing the correct dose warrants careful consideration of
the prevailing dose criteria that differ per NOAC. Elec-
tronic systems are useful to intercept prescriptions
that are incorrect based on simple ‘primary’ criteria,
for example dosing frequency and drug-drug interac-
tions with concomitant medication. However, these
systems do not take into account patient characteris-
tics such as age, renal function or weight, which are
crucial elements to determine the NOAC dose.
Methods Our goal was to determine the appropriate-
ness of all prescriptions, as compared with the prod-
uct labelling approved by the European Medicines
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Agency, to address common pitfalls in prescribing
NOACs. AF patients with a first NOAC prescription
between January 2012 and December 2016 were iden-
tified from our electronic hospital information system
(Martini Hospital, Groningen, the Netherlands).
Results The study included 3,231 AF patients who
had started on an NOAC; 10.7% received an inappro-
priate dose and the appropriateness of the prescrip-
tion could not be determined in 14.1%. Underdosing
and overdosing occurred in 5.4% and 4.5% of all pre-
scriptions, respectively. A reduced-dose NOAC was
a predictor for incorrect prescribing (odds ratio: 2.70,
95% confidence interval: 2.13–3.41). Patient factors
were identified that predicted incorrect prescriptions
for dabigatran and apixaban.
Conclusion An incorrect prescription occurred more
often in the reduced-dose NOAC group. Clinical pa-
rameters such as renal function are often unknown
whilst these are essential to determine the right NOAC
and dose.
What’s new?
 Incorrect prescribing of non-vitamin K antago-
nist oral anticoagulants (NOACs) occurs more
often in the reduced-dose NOAC group (apixa-
ban 2.5mg, dabigatran 110mg and rivaroxaban
15mg) compared with the full-dose group.
 The renal function was unknown in 13.9% of the
patients whilst this is one of the crucial factors to
determine the appropriateness of the prescrip-
tion.
 Older age (≥80 years) was a predictor for incor-
rect apixaban prescriptions. Reduced renal func-
tion and verapamil use were predictors for incor-
rect dabigatran prescriptions.
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Introduction
The non-vitamin K antagonist oral anticoagulants
(NOACs) are prescribed to patients with atrial fib-
rillation (AF) to reduce the risk of stroke. NOACs
have a direct, predictable therapeutic effect allowing
a fixed-dose regimen [1–5]. The correct prescribed
dose of the NOACs is determined by several patient
characteristics and also concomitant medication use.
Prescribing the correct NOAC dose warrants careful
consideration of the prevailing dose criteria that differ
per NOAC. Several larger studies have been carried
out to evaluate prescribing patterns of NOACs, fo-
cusing on prescription errors. These studies found
a large variety in error rates in prescriptions ranging
from 9 to 49%, although most were around 9.7% to
28% [6–13]. Computerised physician order entry is
generally supported by a basic level of clinical deci-
sion support to assure correct prescribing. Electronic
systems are useful to intercept incorrect prescriptions
based on simple ‘primary’ criteria, for example the
dosing frequency and drug-drug interactions. How-
ever, these systems do not take into account patient
characteristics such as age, renal function or weight,
which determine the appropriate choice of a spe-
cific NOAC and the dose. Inadequate dosing can
influence the effectiveness and safety of these oral
anticoagulants. As a case study, we have explored the
prescription policy within our large teaching hospital.
Our goal was to determine the appropriateness of all
prescriptions, as compared with the product labelling
approved by the European Medicines Agency (EMA),
to explore common pitfalls in prescribing NOACs.
Method
This study was a retrospective, cohort study on NOAC
prescriptions in AF patients who started anticoagula-
tion therapy in our hospital (Martini Hospital, Gronin-
gen, the Netherlands) between 1 January 2012 and
13 December 2016. All data were collected from the
electronic hospital information system (HiX, Chipsoft,
Amsterdam, the Netherlands). The study included all
inpatient and outpatient prescriptions. Patients were
included in the study if they had at least one NOAC
prescription within the study period and had an AF
diagnosis in their electronic medical file confirmed
by a cardiologist. The first prescription of the fol-
lowing NOACs was included based on the Anatomi-
cal Therapeutic Classification (ATC): B01AF02 (apixa-
ban), B01AE07 (dabigatran), B01AF03 (edoxaban) and
B01AF01 (rivaroxaban). The index date was the date
that an NOAC was initiated.
Outcomes and definitions
The eligibility of oral anticoagulation for stroke pre-
vention in AF was determined by a patient’s stroke risk
by means of the CHA2DS2-VASc score; women with
a CHA2DS2-VASc score of ≥2 and men with a CHA2DS2-
VASc score of ≥1 were eligible for an oral anticoagulant
[14, 15]. The primary outcomes included the percent-
age of inappropriate prescribing and the reasons for
a prescription being classified as inappropriate. A pre-
scription was reported as inappropriate if the patient
had ≥1 inappropriate dosing criteria according to the
European Society of Cardiology (ESC) guideline for AF
and the summary of product characteristics (SmPCs)
as registered with the EMA. The dosing criteria that
were used to evaluate the appropriateness of the pre-
scriptions are summarised in the online Supplemen-
tary Material, Table S1. Prescriptions that were classi-
fied as inappropriate solely based on a missing value
or multiple missing values were reported as ‘unknown
inappropriateness’. All incorrect prescriptions, over-
dosed or underdosed, were considered ‘actionable in-
terventions’ where the stroke prevention needed op-
timisation. The action could be a dose reduction, an
increase in the dose or a switch to another NOAC if
contraindicated.
Statistical analysis
IBM SPSS Statistics for Windows (Version 20.0. Ar-
monk, NY: IBM Corp.) was used to perform all data
handling, to calculate the CHA2DS2-VASc score and
the bleeding score (HAS-BLED), and to perform all
statistical analyses. Descriptive statistics included
mean and standard deviation (SD) for continuous
variables; numbers and percentages were calculated
for categorical variables. Logistic regression was per-
formed to determine if there was a difference in
incorrect prescriptions based on full-dose (apixaban
5mg, dabigatran 150mg and rivaroxaban 20mg) ver-
sus reduced dose (apixaban 2.5mg, dabigatran 110mg
and rivaroxaban 15mg) and to explore predictive fac-
tors for incorrect prescriptions per NOAC type. The
factors included in the regression analyses were all
transformed to a binary variable according to the
dose criterion, i. e. for dabigatran: age ≥75 years or
<75 years; renal function (estimated glomerular filtra-
tion rate) >50 or ≤50ml/min, verapamil use yes/no.
Predictive factors were only included if there were at
least 10 observations in both categories. A trend anal-
ysis on incorrect prescriptions was performed with
a Chi-squared test and linear regression. All analyses
were considered statistically significant when p<0.05.
Results
The study identified 3,291 unique patients who were
prescribed an NOAC (apixaban 2.5mg or 5mg, dabi-
gatran 75mg, 110mg or 150mg, edoxaban 30mg or
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– full dosea, n (%)
2,112 (65.4) 769 (84.1) 1,184 (55.6) 159 (85.5)
– reduced doseb, n (%) 1,095 (33.9) 145 (15.9) 930 (43.6) 20 (10.7)
– other dosec, n (%) 24 (0.7) – 17 (0.8) 7 (3.8)
sex: male, n (%) 1,783 (55.2) 484 (53.0) 1,173 (55.0) 126 (67.7)
age (years), median (range) 72.0 (26.0–101.0) 73.0 (31.0–99.0) 71.0 (26.0–101.0) 69.0 (42.0–95.0)
– ≥75 years, n (%) 1,279 (39.6) 337 (36.9) 810 (38.0) 53 (28.5)
weight ≤60kg, n (%) 153 (4.7) 52 (5.7) 96 (4.5) 5 (2.7)
renal function (ml/min)d, mean ± SD 72.3 ± 18.4 68.9 ± 20.3 73.8 ± 17.4 72.6 ± 16.0
– 30–50ml/min, n (%) 284 (8.8) 133 (14.6) 138 (6.5) 11 (5.9)
– <30ml/min, n (%) 15 (0.5) 10 (1.1) 4 (0.2) 1 (0.5)
– unknown 448 (13.9) 107 (11.7) 304 (14.3) 37 (19.9)
comorbidity, n (%)
– CVA/TIA
385 (11.9) 106 (11.6) 265 (12.4) 14 (7.5)
– hypertension 1,939 (60.0) 556 (60.8) 1,283 (60.2) 100 (53.8)
– heart failure 274 (8.5) 92 (10.1) 174 (8.2) 8 (4.3)
– vascular diseasee 543 (16.8) 174 (19.0) 344 (16.1) 25 (13.4)
– diabetes mellitus 526 (16.3) 163 (17.8) 340 (16.0) 23 (12.4)
CHA2DS2-VASc score, median (range) 3.0 (0.0–8.0) 3.0 (0.0–8.0) 3.0 (0.0–8.0) 2.0 (0.0–8.0)
HAS-BLED score, median (range) 2.0 (0.0–5.0) 2.0 (0.0–4.0) 2.0 (0.0–5.0) 1.0 (0.0–4.0)
CHA2DS2-VASc congestive heart failure of left ventricular dysfunction, hypertension, age ≥75, diabetes, thromboembolism or stroke history, vascular disease,
age 65–74 years and sex; CVA cerebrovascular accident; HAS-BLED hypertension, renal or liver failure, stroke history, bleeding history, labile international
normalised ratio, age >65, drugs or alcohol; kg kilograms; ml/min millilitres/minute; SD standard deviation; TIA transient ischaemic attack
a 5mg for apixaban, 150mg for dabigatran, 20mg for rivaroxaban
b 2.5mg for apixaban, 110mg for dabigatran, 15mg for rivaroxaban
c 75mg for dabigatran, 10mg for rivaroxaban
d None of the patients had a renal function <15ml/min
e Myocardial infarction and peripheral artery diseases
60mg and rivaroxaban 2.5mg, 10mg, 15mg or 20mg)
between 1 January 2012 and 13 December 2016. There
were no patients with a prescription for edoxaban or
rivaroxaban 2.5mg. Of the identified patients, 3,231
(98.2%) met the predefined inclusion criteria. The
main reason for exclusion was an unknown initia-
tion date (n= 347, 10.5%) or no confirmed diagnosis
of atrial fibrillation (n=260, 7.9%). The patient char-
acteristics for all prescriptions and characteristics per
subgroup of NOAC are summarised in Tab. 1.
The majority of the patients were prescribed dabi-
gatran (66.0%) of which 43.6% received the reduced
dose. Apixaban was prescribed to 28.3% of the pa-
tients of which 15.9% received the reduced dose, ri-
varoxaban was prescribed to 5.7% of the patients of
which 10.7% received the reduced dose. Dabigatran
75mg was prescribed to 17 patients, 0.8% of all dabi-
gatran prescriptions, and rivaroxaban 10mg to 7 pa-
tients, 3.8% of all rivaroxaban prescriptions. The re-
sults of the evaluation of appropriate anticoagulant
prescribing are summarised in Tab. 2. The prescrip-
tions of dabigatran 75mg and rivaroxaban 10mg are
not specified as an NOAC subgroup, as these prescrip-
tions were already inappropriate irrespective of the
other dosing criteria.
An inappropriate first NOAC prescription was iden-
tified in 10.7% of all prescriptions evaluated. All inap-
propriate prescriptions required action to be taken.
Also, 14.1% of all prescriptions were classified as ‘un-
known appropriateness’ because crucial information
was missing to determine whether the prescription
was appropriate or not. The renal function was un-
known in 13.9% of all patients and weight (dosing cri-
terion for apixaban) was unknown in 13.6% of all apix-
aban patients or 3.8% of all patients. Apixaban 2.5mg
was incorrectly prescribed by far the most frequently
(41.4%). Apixaban, dabigatran and rivaroxaban were
underdosed in 14.8% of the reduced dose prescrip-
tions and overdosed in 6.4% of the full dose prescrip-
tions. A detailed description of the reasons for in-
appropriate prescribing or unknown appropriateness
is listed in the online Supplementary Tables 2–7 per
NOAC type and dose. The numbers of correct, in-
correct and unknown appropriate prescriptions per
year are summarised in Fig. 1. A Chi-squared test
showed there was a significant (p< 0.001) difference in
the number of correct, incorrect and unknown appro-
priate prescriptions within the study period. Linear
regression showed that there was a negative correla-
tion between year prescribed and incorrect prescrip-
tions (p< 0.001), indicating that the prescription errors
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Table 2 Categories of primary non-vitamin K oral antagonist prescriptions classified as (unknown) inappropriate including

























inappropriate prescription 345 (10.7) 20 (2.6) 60 (41.4) 117 (9.9) 108 (11.6) 8 (5.0) 8 (40.0)
– underdosedb 174 (5.4) 4 (0.5) 60 (41.4)c 6 (0.5) 97 (10.4) – 7 (35.0)
– overdosedb 147 (4.5) 16 (2.1) – 111 (9.4) 11 (1.2) 8 (5.0) 1 (5.0)
unknown appropriateness 454 (14.1) 113 (14.7) 30 (20.7) 147 (12.4) 129 (13.9) 30 (18.9) 5 (25.0)
missing renal functiond 448 (13.9) 98 (12.7) 9 (6.2) 166 (14.0) 133 (14.3) 30 (18.9) 5 (25.0)
missing weighte 124 (3.8) 96 (12.5) 28 (19.3) – – – –
All results are presented as numbers plus percentage between brackets
AF atrial fibrillation; CHA2DS2-VASc congestive heart failure of left ventricular dysfunction, hypertension, age ≥75, diabetes, thromboembolism or stroke history,
vascular disease, age 65–74 years and sex; kg kilograms
a These prescriptions also include dabigatran 75mg and rivaroxaban 10mg which are not registered for AF within Europe
b According to the dosing criteria as described in the Summary of Product Characteristics approved by the European Medicines Agency. These categories
include: Wrong dosing regimen was classified as underdosed or overdosed (depending on the NOAC dose), prescriptions in patients with CHA2DS2-VASc score
of 1 or less for women and a CHA2DS2-VASc score of 0 for men without a planned electrical cardioversion were classified as overdosed and prescriptions with
a contraindication based on renal function
c This number includes apixaban 2.5mg prescriptions with no dose reduction criteria and prescriptions with only one dose adjustment criterion
d Glomerular filtration rate (ml/min) and serum creatinine (mg/dl) for all prescriptions
e Only counted for apixaban prescriptions for this is the only non-vitamin K oral antagonist with weight as a dose reduction criterion.
occurred more often at the beginning of the study pe-
riod in 2012.
Patients prescribed a reduced dose of the NOAC
(apixaban 2.5mg, dabigatran 110mg and rivaroxaban
15mg) had higher odds to receive an incorrect pre-
scription (OR 2.97; 95% CI 2.13–3.41; p< 0.01). In
the reduced dose NOAC prescriptions, patients aged
≥80 years had lower odds of receiving an inappro-
priate reduced dose (OR 0.37; 95% CI 0.15–0.93). An
analysis of predictive factors was not possible for ri-
varoxaban due to the small sample size; the analy-
sis for apixaban was limited to variables with enough
predictive power to avoid overfitting. In dabigatran
Fig. 1 Time trend of cor-
































prescriptions, an age of ≥75 years had lower odds for
an incorrect prescription (OR 0.38; 95% CI 0.27–0.54;
p< 0.01). The same effect was seen with age ≥80 years
as a cut-off (OR 0.64; 95% CI 0.44–0.93; p= 0.018).
A renal function ≤50ml/min and verapamil use were
predictors for incorrect prescription (OR 2.46; 95%
CI 1.54–3.95 [p< 0.01] and OR 1.88 95% CI 1.34–2.65
[p< 0.01], respectively). The effect of the HAS-BLED
score (categorised as high at ≥3), and sex were not
significant predictors (p= 0.473 and p= 0.485, respec-
tively). For apixaban prescriptions, male sex (OR 0.57
95% CI 0.33–0.98; p=0.043) was a predictor for receiv-
ing the correct prescription and age ≥80 years (OR 7.48
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Fig. 2 Forest plot of the
results of univariate anal-
yses on predictive factors
for incorrect prescribing in
all NOAC prescriptions and
subgroup analyses for apix-
aban, dabigatran and the
reduced dose NOACs
95% CI 4.30–12.99; p<0.01) was a predictor for receiv-
ing an incorrect prescription. A high HAS-BLED score,
weight ≥60kg and serum creatinine ≥133µmol/l were
not significant predictive factors (p=0.124, p= 0.712
and p= 0.100, respectively). All results are summarised
in Fig. 2.
Discussion
Over the last decade there has been a shift in the pre-
scription of oral anticoagulants, with NOACs now by
far the most preferred anticoagulants [16–18]. Evalu-
ating the prescription policy within our hospital over
several years revealed important learning points to
optimise prescribing but also monitoring of stroke
prevention after initiation. Of all 3,231 AF patients
who started on an NOAC, 10.7% received an inap-
propriate dose and the appropriateness of the pre-
scription could not be determined in 14.1%. All incor-
rect prescriptions were actionable, meaning that the
prescription had to be corrected to optimise stroke
prevention, with 5.4% of the prescriptions requiring
a higher dose and 4.5% of all prescriptions requiring
a lower dose. The remaining actionable 0.8% were
prescriptions for doses not registered for stroke pre-
vention, dabigatran 75mg and rivaroxaban 10mg, and
would also require a dose increase. The error rate is
fairly low compared with rates found in other studies,
possibly because most patients with AF are seen at our
specialised AF nurse-led clinic providing integrated
chronic care supervised by a cardiologist [19]. Nurse-
led structured care of patients with AF has been as-
sociated with significantly improved guideline adher-
ence [20]. Another study demonstrated that patient
outcomes (cardiovascular-related hospitalisations and
death) with nurse-led care were at least as good as
in clinical trials [21]. Good outcomes in nurse-led
care could very well be due to higher guideline-ad-
herent antithrombotic treatment [22]. The percentage
of patients with reduced renal function was relatively
low with <10% of the patients having a renal func-
tion (eGFR) <50ml/min. This could indicate that pa-
tients with impaired renal function are still typically
prescribed a vitamin K antagonist. A reduced dose
NOAC was a significant predictor for an incorrect pre-
scription and percentage-wise this was the highest for
apixaban 2.5mg. The same pattern in prescription er-
rors was seen in previous studies [23–26]. In our study,
the prescription of a reduced dose was underdosed in
10.4–41.4% of the reduced dose prescriptions. Patients
who were prescribed an NOAC in a reduced dose had
an OR of 2.97 for receiving an incorrect prescription.
This could indicate that prescribers are hesitant to
prescribe the full NOAC dose. The use of a reduced
dose NOAC without the presence of any dose-reduc-
tion criteria could lead to a sub-optimal reduction of
the stroke risk, although this has not been studied
extensively [13, 27]. Noteworthy, a study in Korean
AF patients demonstrated that guideline-discordant
dabigatran 110mg (n= 183) had a similar efficacy and
safety compared with dabigatran 150mg (n=294) [28].
The effect of age on receiving an incorrect dose in
apixaban and dabigatran prescriptions also illustrates
that physicians tend to choose the low dose. The find-
ing that patients aged ≥80 years had lower odds of
receiving an inappropriate dose reduction compared
with younger patients confirms this hypothesis. This
result was mainly driven by the large proportion of
dabigatran prescriptions. Age is not a single criterion
for apixaban dose reduction and was found to be in-
dicative for an incorrect dose. The high OR for age
in incorrect apixaban prescriptions shows that age is
often used as a single criterion for dose reduction in
apixaban while this is only true in the presence of
a low body weight or renal dysfunction (2 out of 3 cri-
teria). Because age is a single dose reduction criterion
for dabigatran, a low OR for incorrect prescriptions
was found for advanced age. A high bleeding risk,
HAS-BLED score ≥3, was not identified as a significant
predictor for incorrect apixaban or dabigatran pre-
scription. The ESC explicitly mentions that the bleed-
ing risk should be evaluated; however, a high bleeding
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risk should not be a reason to withhold oral anticoag-
ulation [14]. With the prescription of NOACs shifting
more towards primary care, there will be a transition
period in which more attention has to be paid to the
prescribing and monitoring. The same tailor-made
monitoring tools within a hospital can also be used in
primary care.
Recommendations for improving prescribing
The key to correct prescribing of NOACs in AF pa-
tients is the full availability of patient information and
the incorporation of all these patient-specific charac-
teristics into the decision making. Ideally, the NOAC
can only be prescribed if all necessary information is
available. The physician should at least have infor-
mation on age, weight, comorbidities, renal function
(serum creatinine) and concomitant medication. The
pharmacist responsible for checking the medication
should also have full access to this information, which
is required for them to check the prescription before
dispensing. Preferably, the patient’s medical history
and comorbidities should be registered in the elec-
tronic system in such a way that these factors can
be computerised into categorical variables and used
to monitor the appropriateness of the NOAC dose at
a population level. One of the variables most com-
monly unavailable was renal function, although this is
an important factor for determining the correct dose
and also for determining a possible contraindication.
The renal function can decrease rapidly, especially
in older patients, hence periodic monitoring is im-
portant to determine if dose adjustment is necessary.
Guideline adherence to treatment initiation can still
be improved and is a good starting point to decrease
the extent of undertreatment and overtreatment [29].
All physicians who prescribe NOACs should be
aware of the most common prescription mistakes
reported in the present study, namely: 1) inappro-
priate dose reduction in apixaban patients, especially
in those >80 years; 2) inappropriate full-dose dabiga-
tran in patients with using either verapamil or with
an impaired renal function. A pharmacist could also
assist in the prescription process to further reduce
drug-related problems [30]. With the experience of
several years of NOAC prescribing, more attention
now needs to be paid to achieving and maintaining
optimal stroke prevention in the future.
Conclusion
A hospital-based population-level review of first pre-
scriptions of NOACs showed that in at least 10% of
these prescriptions interventions were required to
optimise stroke prevention. Prescription errors oc-
curred more often in the reduced dose NOAC group
(apixaban 2.5mg, dabigatran 110mg and rivaroxaban
15mg). Clinical parameters such as renal function are
often unknown whilst these are essential to determine
the right NOAC type and dose.
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